Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680017 · ClinicalTrials.gov registry record · Phase 3
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT00680017 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 280 participants.
The verdict
NCT00680017, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.
Interventions
- DRUG Rosuvastatin
- DRUG ABT-335 plus rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680017
The ClinicalTrials.gov registry entry for NCT00680017 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00680017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00680017 about?
NCT00680017 is a clinical study titled "30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease". The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.
What is the current status of trial NCT00680017?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2008-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00680017?
The interventions under investigation include: Rosuvastatin (DRUG), ABT-335 plus rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00680017?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.